// App-Quantinova.ai

11006 : Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028A multicenter phase II study.

Researchers

Presenter

  • Hussein Abdul-Hassan Tawbi

Principal Investigators

  • Melissa Amber Burgess

  • John Crowley

  • Brian Andrew Van Tine

  • James Hu

  • Scott Schuetze

  • Sandra P. D'Angelo

  • Steven Attia

  • Dennis A. Priebat

  • Scott H. Okuno

  • Richard F. Riedel

  • Lara Emily Davis

  • Sujana Movva

  • Damon R. Reed

  • Laurence H. Baker

  • Denise K. Reinke

  • Robert G. Maki

  • Shreyaskumar Patel

Medical Centers

  • University of Pittsburgh, Pittsburgh, PA

  • University of Pittsburgh, Pittsburgh, PA

  • Cancer Research and Biostats, Seattle, WA

  • Washington University in St Louis, St. Louis, MO

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • University of Michigan, Ann Arbor, MI

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Mayo Clinic, Jacksonville, FL

  • Medstar Washington Hosp Ctr, Washington, DC

  • Mayo Clinic, Rochester, MN

  • Duke University Medical Center, Durham, NC

  • Oregon Health and Science University, Portland, OR

  • Fox Chase Cancer Center, Philadelphia, PA

  • Moffitt Cancer Center, Tampa, FL

  • SARC, Ann Arbor, MI

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • The University of Texas MD Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Synovial sarcoma

  • Chondrosarcoma

  • Leiomyosarcoma

  • Bone Cancer

  • Ewing's sarcoma

  • Osteosarcoma

  • Liposarcomas

  • Sarcoma

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Programmed cell death protein 1

  • Tumor protein p63

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02301039

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved